Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Infant approximately 2 months of age (42 days to 90 days), inclusive~* In good health~Exclusion Criteria:~* Prior administration of any pneumococcal vaccine~* Known hypersensitivity to any component of the pneumococcal conjugate vaccine or any diphtheria toxoid-containing vaccine~* Known or suspected impairment of immunological function~* History of congenital or acquired immunodeficiency (eg, splenomegaly)~* Mother has documented human immunodeficiency virus (HIV) infection~* Mother has documented hepatitis B surface antigen-positive test result~* Known or history of functional or anatomic asplenia~* History of failure to thrive~* History of a coagulation disorder~* History of autoimmune disease~* Known neurologic or cognitive behavioral disorder~* Expects to require systemic corticosteroids within 30 days after each vaccination during the trial~* Prior administration of a blood transfusion or blood products, including immunoglobulin~* Participated in another clinical trial of an investigational product~* History of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- V114 Lot 1 (Type: EXPERIMENTAL): Infants will receive a 0.5 mL intramuscular injection of V114 Lot 1 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
- V114 Lot 2 (Type: EXPERIMENTAL): Infants will receive a 0.5 mL intramuscular injection of V114 Lot 2 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
- Prevnar 13™ (Type: ACTIVE_COMPARATOR): Infants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)

Based on this trial design, predict the completion outcome and termination type (if applicable).